One Year's Treatment of Paget's Disease of Bone by Synthetic Salmon Calcitonin as a Nasal Spray

[en] The effectiveness of synthetic salmon calcitonin (SCT) administered as a nasal spray was assessed via clinical, biological, and radiological variables in 17 previously untreated Pagetic patients over a 1-year course of therapy. The results showed a highly significant decrease of serum alkaline phosphatase (S-ALP) (p less than 0.05 after 1 month of treatment) and of the urinary hydroxyproline/creatinine ratio (OH/Cr) (p less than 0.01 after 1 month of treatment). For the whole group, the mean decrease in S-ALP was 37 +/- 4% (SEM) after 6 months (p less than 0.01) and 31 +/- 5% after 1 year (p less than 0.01). The mean fall in OH/Cr was 35 +/- 6% (SEM) (p less than 0.01) and 37 +/- 7% (p less than 0.01) after 6 and 12 months, respectively. None of the usual side-effects of SCT were reported and local tolerance was excellent throughout the study.

Disciplines :

Rheumatology

Author, co-author :

Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique

JEUGMANS, Anne-Marie ; Université de Liège - ULiège

Albert, Adelin ; Université de Liège - ULiège > Département des sciences de la santé publique > Informatique médicale et biostatistique

Denis, D.; Université de Liège - ULiège

Franchimont, Paul; Université de Liège - ULiège

Language :

English

Title :

One Year's Treatment of Paget's Disease of Bone by Synthetic Salmon Calcitonin as a Nasal Spray

Publication date :

June 1988

Journal title :

Journal of Bone and Mineral Research

ISSN :

0884-0431

eISSN :

1523-4681

Publisher :

Wiley, Washington, United States - District of Columbia

Volume :

Issue :

Pages :

249-52

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 12 June 2012

Statistics

Number of views

111 (2 by ULiège)

Number of downloads

4 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Raisz L, Av WY, Friedman J, Nieman I (1967) Thyrocalcitonin and bone resorption. Amer J Med 43:684-690.
Bijvoet OL, Jansen A (1967) Thyrocalcitonin in Paget's disease. Lancet 2:472.
Bijvoet OL, Veer, Jansen AP (1968) Effects of calcitonin on patients with Paget's disease, thyrotoxicosis or hypercalcaemia. Lancet 1:876-881.
Eisinger J, Laponche AM (1976) Traitement discontinu de la maladie de Paget par la calcitonine. Rev Rhum Mal Osteo‐Artic 43:511-516.
Evans GA, Slee GC, Calcitonin for multiple fractures in Paget's disease. Br Med J pp, 357; 1977, 274.
de Rose J, Singer F, Avramides A, Flores A, Dziadiw R, Baker R, Wallach S (1974) Response of Paget's disease to porcine and salmon calcitonins‐effects of long‐term treatment. The American Journal of Medicine 56:858-866.
Gennari C, Cecchetin M, Passeri M, Francini G, Gonnelli S, Nami R, Bigazzi S (1983) Gli effetti collaterali di differenti calcitonine. Calcitonin in man , Gennari C, Segre G, (eds), Masson, Milano; 93-101.
Reginster JY, Franchimont P (1985) La calcitonine 25 ans après. Méd Hyg 43:3808-3814.
Fink G, Gennser G, Liedholm P, Thoreil J (1974) Comparison of plasma levels of LH‐RH in men after intravenous and intranasal administration. J Endocrinol 63:351-360.
Pontiroli AE, Alberetto M, Secchi A, Dossi G, Bosi I, Pozza G (1982) Insulin given intranasally induces hypocalcaemia in normal and diabetic subjects. Br Med J 284:303-306.
Pontiroli AE, Alberetto M, Pozza G (1983) Intransal glucagon raises blood glucose concentration in healthy volunteers. Br Med J 287:462-463.
Murlin JR, Gibb CBF, Romansky MJ, Steinhausen TB, Truax FL (1940) Effectiveness of perioral insulin in human diabetes. Am J Physiol 120:709-722.
Reginster JY, Albert A, Franchimont P (1985) Salmon calcitonin nasal spray in Paget's disease of bone: Preliminary results in five patients. Calcif Tiss Int 37:577-580.
Trayser KA, Seligson D (1969) A new kinetic method for enzyme analysis suitable for automation. Clin Chem 15:452.
Arnaud CD, Tsao HS, Littledike T (1970) Radioimmunoassay of parathyroid hormone in serum. J Clin Invest 50:21-25.
Zerbe GO (1979) Randomization analysis of the completely randomized design extend to growth and response curves. Journal of the American Statistical Association 74:215-221.
Reginster JY, Gritten C, Diverse P, Hauwaert C, Crieelard JM, Halleux R, Franchimont P (1985) Traitement de la maladie de Paget par l'étidronate disodique à faible dose. Apparition de leueopénies transitoires réversibles suspectes. Rev Rhum Mal Osteo‐Art 52:145-150.
Evans RG, Slee GC (1968) The hereditary aspects of Paget's disease. JAMA: The Journal of the American Medical Association 205:900-902.
Shai F, Baker R, Wallach S (1971) The clinical and metabolic effects of porcine calcitonin on Paget's disease of the bone. J Clin Invest 50:1927-1940.
Reginster JY, Denis D, Albert A, Franchimont P (1987) Assessment of the biological effectiveness of nasal synthetic salmon calcitonin (SSCT) by comparison with intramuscular (i.m.) or placebo injection in normal subjects. Bone Min 2:133-140.
de Deuxchaines, Devogelaer JP, Huaux JP, Dufour JP, Esselinckx W, Engelbeen JP, Stasse P, Hermans P, de Buisseret JP (1987) New modes of administration of salmon calcitonin in Paget's disease. Nasal spray and suppository. Clin Orthop 217:56-71.
Avramides A (1977) Salmon and porcine calcitonin treatment of Paget's disease of bone. Clin Orthop Rel Res 127:78-85.
Kanis JA, Strong JA (1974) Calcitonin and plasma‐phosphate in Paget's disease. Lancet 1:987.
Reginster JY, Franchimont P (1985) Side effects of synthetic salmon calcitonin given by intranasal spray compared with intramuscular injection. Clin Exp Rheum 3:155-157.
Reginster JY, Denis D, Albert A, Deroisy R, Lecart MP, Fontaine MA, Lambelin P, Franchimont P (1987) One year controlled randomised trial of early postmenopausal bone loss by intranasal calcitonin. Lancet 2:1481-1487.